Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P
Department of Pharmacology, University of Milan, Milan, and Unit of Rheumatology, A.O. Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Int J Clin Pract. 2007 Aug;61(8):1270-7. doi: 10.1111/j.1742-1241.2007.01453.x. Epub 2007 Jun 22.
This study was designed to investigate the analgesic effects of nimesulide and celecoxib in patients with knee osteoarthritis (OA). In patients with joint effusion, the effects of these non-steroidal anti-inflammatory drugs (NSAIDs) on synovial fluid concentrations of substance P (SP), interleukin (IL)-6 and IL-8 also were evaluated.
Patients were randomly assigned either nimesulide (100 mg twice a day) or celecoxib (200 mg once a day) for 2 weeks. The intensity of joint pain was assessed with a 100-mm visual analogue scale (VAS). Furthermore, patients completed questions about analgesic efficacy and overall tolerability of the treatments on a five-point categorical scale. Synovial fluid samples were drawn at baseline, 30 min after the first drug intake (day 1), and 30 min after the last drug intake (day 14).
We enrolled 44 patients, 20 of whom had a joint effusion. In this group, the effects of nimesulide were more marked than for celecoxib, with evidence of a faster onset of the analgesic action. Both after a single or repeated administration, nimesulide significantly reduced the synovial fluid concentrations of SP and IL-6. Celecoxib, on the other hand, did not change the concentrations of SP and significantly reduced the levels of IL-6 only on day 14. None of the drugs affected IL-8. Both drugs were generally well tolerated.
These results provide evidence that nimesulide is an effective agent for the symptomatic treatment of OA. The effect on inflammatory pain mediators is consistent with the fast analgesic action of this NSAID.
本研究旨在调查尼美舒利和塞来昔布对膝骨关节炎(OA)患者的镇痛效果。对于有关节积液的患者,还评估了这些非甾体抗炎药(NSAIDs)对滑膜液中P物质(SP)、白细胞介素(IL)-6和IL-8浓度的影响。
患者被随机分配接受尼美舒利(100mg,每日两次)或塞来昔布(200mg,每日一次)治疗,为期2周。采用100mm视觉模拟量表(VAS)评估关节疼痛强度。此外,患者还需就治疗的镇痛效果和总体耐受性,按五分制分类量表回答相关问题。在基线、首次服药后30分钟(第1天)和末次服药后30分钟(第14天)采集滑膜液样本。
我们纳入了44例患者,其中20例有关节积液。在该组中,尼美舒利的效果比塞来昔布更显著,有证据表明其镇痛作用起效更快。单次或重复给药后,尼美舒利均能显著降低滑膜液中SP和IL-6的浓度。另一方面,塞来昔布并未改变SP的浓度,仅在第14天显著降低了IL-6的水平。两种药物均未影响IL-8。两种药物总体耐受性良好。
这些结果表明,尼美舒利是OA症状性治疗的有效药物。其对炎性疼痛介质的作用与这种NSAID的快速镇痛作用一致。